MX2019007703A - Diagnostico. - Google Patents
Diagnostico.Info
- Publication number
- MX2019007703A MX2019007703A MX2019007703A MX2019007703A MX2019007703A MX 2019007703 A MX2019007703 A MX 2019007703A MX 2019007703 A MX2019007703 A MX 2019007703A MX 2019007703 A MX2019007703 A MX 2019007703A MX 2019007703 A MX2019007703 A MX 2019007703A
- Authority
- MX
- Mexico
- Prior art keywords
- map
- fragment
- diagnostic
- diagnosing
- antigen
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Computational Biology (AREA)
Abstract
Un método para diagnosticar o monitorear la infección por Mycobacterium avium subespecie paratuberculosis (MAP), método que comprende detectar la presencia del polipéptido (MAP P900) codificado por la cadena positiva de IS900, o un fragmento del mismo, en una muestra de un sujeto, en donde MAP P900, o un fragmento del mismo, se detecta usando un anticuerpo, o un fragmento de unión a antígeno del mismo, que se une a MAP P900.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1700487.0A GB201700487D0 (en) | 2017-01-11 | 2017-01-11 | Diagnostic |
| PCT/GB2018/050075 WO2018130836A1 (en) | 2017-01-11 | 2018-01-11 | Diagnostic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007703A true MX2019007703A (es) | 2019-12-16 |
Family
ID=58463962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007703A MX2019007703A (es) | 2017-01-11 | 2018-01-11 | Diagnostico. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20200041509A1 (es) |
| EP (1) | EP3568698A1 (es) |
| JP (1) | JP7418215B2 (es) |
| KR (1) | KR102487240B1 (es) |
| CN (1) | CN110476065B (es) |
| AU (1) | AU2018208079A1 (es) |
| BR (1) | BR112019014299A2 (es) |
| CA (1) | CA3049498A1 (es) |
| GB (1) | GB201700487D0 (es) |
| IL (1) | IL267982A (es) |
| MA (1) | MA47259A (es) |
| MX (1) | MX2019007703A (es) |
| SG (1) | SG11201906189WA (es) |
| WO (1) | WO2018130836A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700487D0 (en) | 2017-01-11 | 2017-02-22 | Hermon-Taylor John | Diagnostic |
| GB201811382D0 (en) * | 2018-07-11 | 2018-08-29 | Taylor John Hermon | Vaccine |
| BR112021001864B1 (pt) * | 2018-08-01 | 2022-08-23 | Cdx Medical Ip, Inc | Sistema para geração de uma imagem digital composta de uma amostra biológica |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8709803D0 (en) | 1987-04-24 | 1987-05-28 | Mcfadden J J | Treatment of crohn's disease &c |
| US5225324A (en) | 1987-04-24 | 1993-07-06 | Bioscience International, Inc. | Diagnostics for mycobacteria in public health, medical, and veterinary practice |
| GB9526178D0 (en) | 1995-12-21 | 1996-02-21 | Taylor John Hermon | Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy |
| GB9806093D0 (en) | 1998-03-20 | 1998-05-20 | Taylor John Hermon | Diagnostics and vaccines for mycobacterial infections of animals and humans |
| AU2003202826B9 (en) * | 2002-01-11 | 2008-06-19 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Diagnostics and vaccines for mycobacterium paratuberculosis infections |
| US7074559B2 (en) | 2002-03-06 | 2006-07-11 | Refents of the University of Minnesota | Mycobacterial diagnostics |
| US7786288B2 (en) * | 2003-10-23 | 2010-08-31 | Karp Nelson M | Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site |
| US20090011426A1 (en) * | 2004-08-19 | 2009-01-08 | Mackintosh James A | Methods of Diagnosis and Treatment of M.Tuberculosis Infection and Reagents Therefor |
| DE602006018872D1 (de) | 2005-02-16 | 2011-01-27 | Cornell Res Foundation Inc | Zusammensetzungen zur auslösung einer immunreaktiocterium avium |
| US7892566B2 (en) | 2005-08-09 | 2011-02-22 | Hav Vaccines Limited | Immunogenic constructs |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2459214A1 (en) | 2009-07-30 | 2012-06-06 | Pfizer Vaccines LLC | Antigenic tau peptides and uses thereof |
| US9109249B2 (en) | 2011-05-19 | 2015-08-18 | University Of Central Florida Research Foundation, Inc. | Microbe detection via hybridizing magnetic relaxation nanosensors |
| WO2014016737A1 (en) | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| US20140116353A1 (en) | 2012-10-31 | 2014-05-01 | Gilles R.G. Monif | Fuidi herd management and risk stratification methods |
| WO2015042704A1 (en) | 2013-09-24 | 2015-04-02 | University Of Guelph | Biomarkers for mycobacterium avium paratuberculosis (map) |
| GB201700487D0 (en) | 2017-01-11 | 2017-02-22 | Hermon-Taylor John | Diagnostic |
| GB201811382D0 (en) | 2018-07-11 | 2018-08-29 | Taylor John Hermon | Vaccine |
-
2017
- 2017-01-11 GB GBGB1700487.0A patent/GB201700487D0/en not_active Ceased
-
2018
- 2018-01-11 US US16/476,656 patent/US20200041509A1/en not_active Abandoned
- 2018-01-11 CA CA3049498A patent/CA3049498A1/en active Pending
- 2018-01-11 MA MA047259A patent/MA47259A/fr unknown
- 2018-01-11 BR BR112019014299-1A patent/BR112019014299A2/pt unknown
- 2018-01-11 CN CN201880017768.6A patent/CN110476065B/zh active Active
- 2018-01-11 MX MX2019007703A patent/MX2019007703A/es unknown
- 2018-01-11 AU AU2018208079A patent/AU2018208079A1/en active Pending
- 2018-01-11 WO PCT/GB2018/050075 patent/WO2018130836A1/en unknown
- 2018-01-11 SG SG11201906189WA patent/SG11201906189WA/en unknown
- 2018-01-11 EP EP18701926.0A patent/EP3568698A1/en active Pending
- 2018-01-11 KR KR1020197023411A patent/KR102487240B1/ko active IP Right Grant
- 2018-01-11 JP JP2019557690A patent/JP7418215B2/ja active Active
-
2019
- 2019-07-10 IL IL267982A patent/IL267982A/en unknown
-
2021
- 2021-06-15 US US17/348,428 patent/US11714085B2/en active Active
-
2023
- 2023-06-09 US US18/332,263 patent/US20230400462A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230400462A1 (en) | 2023-12-14 |
| JP7418215B2 (ja) | 2024-01-19 |
| WO2018130836A1 (en) | 2018-07-19 |
| BR112019014299A2 (pt) | 2020-02-18 |
| KR102487240B1 (ko) | 2023-01-10 |
| CN110476065A (zh) | 2019-11-19 |
| EP3568698A1 (en) | 2019-11-20 |
| SG11201906189WA (en) | 2019-08-27 |
| GB201700487D0 (en) | 2017-02-22 |
| JP2020507084A (ja) | 2020-03-05 |
| US20200041509A1 (en) | 2020-02-06 |
| IL267982A (en) | 2019-09-26 |
| CN110476065B (zh) | 2024-05-31 |
| US20220065855A1 (en) | 2022-03-03 |
| CA3049498A1 (en) | 2018-07-19 |
| MA47259A (fr) | 2019-11-20 |
| US11714085B2 (en) | 2023-08-01 |
| KR20190104589A (ko) | 2019-09-10 |
| AU2018208079A1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007703A (es) | Diagnostico. | |
| GB2569262A (en) | Systems and methods for in-vehicle predictive failure detection | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| RU2018124339A (ru) | Способ и система для сенсорного обнаружения посредством модифицированной наноструктуры | |
| EP4234356A3 (en) | Remote verification of the number of passengers in an autonomous vehicle | |
| MX2022003794A (es) | Sistema que tiene deteccion automatizada de rutas e iniciacion de aplicaciones. | |
| MX2016011377A (es) | Metodo para diagnosticar cancer colorrectal a partir de una muestra de heces humanas por pcr cuantitativa, cebadores y equipo. | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| WO2013134741A3 (en) | Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results | |
| MX2021008520A (es) | Metodos y sistemas para deteccion de analitos. | |
| WO2016161088A3 (en) | Biosensor system for the rapid detection of analytes | |
| MX2019002883A (es) | Un metodo para detectar la entrada de un pasajero a una cabina de elevador de un sistema de elevador. | |
| IN2013MU02326A (es) | ||
| WO2017127731A8 (en) | Nmr methods and systems for the rapid detection of bacteria | |
| WO2014053996A3 (en) | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs | |
| JP2017502253A5 (es) | ||
| NZ751481A (en) | Metabolite biomarkers for diseases associated with the contact activation system | |
| EP2765411A3 (en) | Test strip, detecting device and detecting method | |
| WO2016096066A8 (de) | Verfahren zum betreiben einer bedienvorrichtung eines kraftfahrzeugs in unterschiedlichen bedienmodi sowie bedienvorrichtung und kraftfahrzeug | |
| PL412309A1 (pl) | Sposób wykrywania i/lub identyfikacji pierwotniaków z rodzaju Babesia, starter do zastosowania w tym sposobie oraz zestaw do stosowania w sposobach diagnostyki objawowej i bezobjawowej babeszjozy | |
| RU2017115663A (ru) | Способы и системы для отличия синдрома раздраженного кишечника от воспалительного заболевания кишечника и глютеновой болезни | |
| EP4299586A3 (en) | Methods and compositions for the detection and diagnosis of renal disease and periodontal disease | |
| EP3745132A3 (en) | Detecting sepsis | |
| WO2015095862A3 (en) | Microrna biomarkers for ovarian cancer | |
| WO2012139052A3 (en) | Antibody biomarkers for diabetes |